Table 3.

HR, with 95% CI and p values, for the effect of RA, AS, PsA, SLE and SSc on all-cause mortality of the entire patient cohort for the first 3 years (0–36 months) and for the following 2 years (>36 months) of follow-up

Variable	Entire cohort, 0–36 months of follow-up			Entire cohort, >36 months of follow-up
	HR (main effect)			HR (main effect)
		95% CI	P value		95% CI	P value
RA	0.63	0.60 to 0.66	<0.001	1.13*	1.05 to 1.22	0.002
AS	0.62	0.50 to 0.77	<0.001	1.01**	0.76 to 1.33	0.958
PsA	0.68	0.59 to 0.78	<0.001	1.06*	0.88 to 1.28	0.537
SLE	1.52	1.35 to 1.70	<0.001	1.98**	1.67 to 2.33	<0.001
SSc	2.27	1.89 to 2.74	<0.001	4.24*	3.19 to 5.63	<0.001

P value for interaction *<0.001; **<0.05.

AS, ankylosing spondylitis; PsA, psoriatic arthritis; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus; SSc, systemic sclerosis.